Generics’ giant Mylan Laboratories was granted a US court order in September 2010 prohibiting Apotex, a Canadian pharma company, from selling paroxetine. The order also prohibits GlaxoSmithKline (GSK) from supplying Paxil CR (paroxetine extended-release tablets) to Apotex. Mylan has an exclusive agreement to sell a copy of GSK’s Paxil CR. If GSK were to authorise additional sales of generic paroxetine this would undercut sales and cause an “irretrievable loss of market share and customers” for generic Paxil CR, a Mylan spokesman said.
Mylan granted US restraining order over sales of paroxetine
Home/Pharma News
|
Posted 12/11/2010
0
Post your comment
Mylan had said it received patent licenses and the right to market generic versions of all three dosage strengths of the drug under a 2007 patent lawsuit settlement with GlaxoSmithKline. The agreement had provisions to allow other generic versions of Paxil CR to enter the market before the patent expired. GSK has not followed those terms, Mylan said.
GSK “did not breach any contractual duties owed to Mylan and intends to defend these allegations vigorously,” said a spokeswoman for the company. The court has scheduled further hearings for 18 October 2010.
References
Mylan Press Release. Mylan Granted Temporary Restraining Order Against GlaxoSmithKline and Apotex Prohibiting the Supply, Sale and/or Importing of a Generic Version of Paxil CR. 21 September 2010.
Mylan had said it received patent licenses and the right to market generic versions of all three dosage strengths of the drug under a 2007 patent lawsuit settlement with GlaxoSmithKline. The agreement had provisions to allow other generic versions of Paxil CR to enter the market before the patent expired. GSK has not followed those terms, Mylan said.
GSK “did not breach any contractual duties owed to Mylan and intends to defend these allegations vigorously,” said a spokeswoman for the company. The court has scheduled further hearings for 18 October 2010.
Guidelines
New guidance for biologicals in Pakistan and Hong Kong’s independent drug regulatory authority
Canada poised to remove requirement for Phase III trials for biosimilars
Policies & Legislation
Argentina streamlines drug approval process
ANVISA tackles 24-month backlog in biologicals post-registration petitions
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Formycon signs new aflibercept biosimilar pacts and launches ranivisio in Europe
Bio-Thera and Stada expand biosimilars alliance to include tocilizumab
Global partnerships for biosimilar commercialization announced
New denosumab and ustekinumab biosimilar launches in US, Canada and Japan
Related content
Formycon signs new aflibercept biosimilar pacts and launches ranivisio in Europe
Home/Pharma News Posted 13/11/2025
Bio-Thera and Stada expand biosimilars alliance to include tocilizumab
Home/Pharma News Posted 20/10/2025
New denosumab and ustekinumab biosimilar launches in US, Canada and Japan
Home/Pharma News Posted 10/07/2025
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment